Indication
Non-metastatic Castration-resistant Prostate Cancer
5 clinical trials
3 products
1 drug
Product
DarolutamideClinical trial
DEAR: Use of Darolutamide, Enzalutamide and Apalutamide in the Real-world for Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)Status: Completed, Estimated PCD: 2023-06-30
Product
ApalutamideProduct
EnzalutamideClinical trial
Post-marketing Surveillance Study for Approved Darolutamide Use in Korean PatientsStatus: Not yet recruiting, Estimated PCD: 2025-09-30
Clinical trial
ARI Treatment Use and Outcomes in Non-metastatic Prostate Cancer (nmPC) Patients in the USStatus: Completed, Estimated PCD: 2024-04-04
Clinical trial
A Single-arm, Open-label Phase 4 Study of Darolutamide in Addition to Standard Androgen Deprivation Therapy for Participants in India With High-risk Non-metastatic Castration-resistant Prostate Cancer (nmCRPC)Status: Recruiting, Estimated PCD: 2026-01-28
Clinical trial
Use of Darolutamide, Enzalutamide and Apalutamide for Non-metastatic Castration-Resistant Prostate Cancer (nmCRPC) - EXTension of the DEAR Real-world Study (NCT05362149)Status: Active (not recruiting), Estimated PCD: 2024-05-31
Drug
enzalutamide